A DEEPER DIVE INTO PSYCHIATRY

AN INTEGRATED ADVANTAGE

As a full-service and therapeutically-focused CRO, Medpace specializes in the design and conduct of global trials in neuroscience clinical research, including psychiatry. We bring a global footprint, strategic medical, regulatory, and operational leadership as well as fully integrated Central Labs and Core Imaging services to accelerate psychiatric studies.

• Highly relevant operational know-how and subject matter expertise in psychiatry and neurology drug development
• A well-profiled network of investigative sites enables timely enrollment and high-quality conduct of trials
• A team of Clinical Research Associates and Clinical Trial Managers experienced in psychiatric research
• Integrated imaging and central laboratory services, ensuring seamless logistics, review, and testing

THERAPEUTICALLY-FOCUSED TEAM

Medpace is unique in its scientifically-driven approach to clinical research. Our model gives Sponsors the advantage of early and ongoing insight and guidance from a team of therapeutic experts throughout the trial design and execution. Our highly experienced team of medical, regulatory, and operational experts work collaboratively to conduct clinical trials. We understand issues from the perspectives of Sponsors, clinical investigators, scientific leaders, and reviewers at regulatory agencies. With this insight, we successfully define and execute clear development plans from beginning to end.

Accelerate your psychiatric studies with Medpace's full-service team of medical and regulatory experts, highly-experienced clinical trial management teams, central labs, and core imaging labs.
EXPERT INSIGHT

Serving as therapeutic team leaders, our in-house medical doctors apply years of psychiatric drug development experience to each study. Our medical leaders provide strategic direction for study design and planning, train operational staff, work with Investigators, provide medical monitoring, and meet with regulatory agencies as well as our global regulatory affairs experts to provide strategic guidance into the best pathways to accelerate approvals. Medpace MDs are embedded throughout every study, providing greater depth of expertise and the ability to tackle complex and challenging diseases.

Sarah DeRossett, MD, PhD
Senior Medical Director, Medical Department, Neurology, Psychopharmacology, Analgesia

Dr. Sarah DeRossett is a board-certified neurologist with 15 years of experience in clinical and academic neurology, plus more than 10 years of drug development experience.

Experience Summary
- Drug development expertise in neuropsychiatric disorders, dementia, opioid use disorder, sleep, and other CNS disorders
- Clinical and drug development experience in pain and analgesia
- Extensive research experience in psychopharmacology with special focus on opioids
- Leadership of clinical development programs in Parkinson’s disease, Alzheimer’s disease, Migraine, Restless Leg Syndrome (RLS), Neuropathic pain, Epilepsy, and Opioid Use Disorder
- Broad experience in pharmaceutical R&D, including single point of accountability for clinical development plans, medical governance, and support of regulatory submissions
- Well-published in the peer-reviewed medical and scientific literature

Education Summary
- Doctor of Medicine, cum laude, Emory University School of Medicine
- Postdoctoral Fellowship, Pharmacology, Emory University School of Medicine
- Residency in Neurology, The Johns Hopkins Hospital
**Toshihiro Hokonohara, MD**  
*Medical Director, Medical Department, Neurology, Psychiatry*

Dr. Toshihiro Hokonohara is a board-certified neurologist with over 15 years of clinical practice and academic neurology including experience in leadership roles at pharmaceutical and global contract research organizations.

**Experience Summary**
- Drug development expertise in neuropsychiatric disorders, dementia, autoimmune disease, oncology and other CNS and Internal Medicine disease
- Clinical and drug development experience in neuro-immunological disease
- Extensive research experience in some neurological hereditary disease
- Pharmacovigilance Leader of clinical development programs in Epilepsy
- Broad experience in pharmacovigilance medical governance and support of regulatory submissions

**Education Summary**
- Doctor of Medicine, Kyushu University – Fukuoka, Japan
- Residency in Neurology, Kyushu University Hospital – Fukuoka, Japan

**Thomas R. Thompson, MD**  
*Vice President, Medical Department, Neurology, Psychiatry*

Dr. Thompson is board certified in both Psychiatry and Geriatric Psychiatry and has over 20 years of phases I-IV clinical development experience.

**Experience Summary**
- Experience in numerous indications including major depression, substance use disorders, bipolar disorders, schizophrenia, anxiety disorders, Parkinson's disease, dementia, epilepsy, headache and pain
- Industry leadership roles with responsibility for clinical development plans, medical affairs, regulatory submissions, medical governance, and medical monitoring
- Leadership and single point of accountability for numerous programs as a previous Director of Neurosciences and Clinical Development for 12 years at a large pharmaceutical company
- Well-published in the peer-reviewed medical and scientific literature

**Education Summary**
- Bachelor of Science, Biology, University of Central Florida
- Doctor of Medicine, Temple University, School of Medicine
- Diplomate, American Board of Neurology and Psychiatry
- Residency in Psychiatry, Emory University School of Medicine
- Fellowship in Geriatric, Emory University School of Medicine
Richard D. Scheyer, MD
Vice President, Medical Department, Neurology, Pharmacology

Dr. Richard Scheyer is a board-certified neurologist with over 30 years of professional medical experience which includes 18 years dedicated to clinical drug development.

Experience Summary
- Pioneer in translational medicine and Phase I/IIa drug development with special interest in early demonstration of clinical efficacy
- Led a team that designed and executed an early development program for next-generation alpha-2 delta ligand, including capsaicin challenge, and crafting Proof of Concept strategy for novel ion channel blockers
- Highly-regarded author with over 60 manuscripts and abstracts, with a focus on clinical pharmacology and therapeutic activity in areas ranging from diabetes to oncology
- Launched first controlled trial natural product-derived protein kinase C activator in Alzheimer's at previous company

Education Summary
- Bachelor of Science, Physics, Stanford University
- Doctor of Medicine, The State University of New York, Upstate Medical University
- Residency in Neurology, Yale University
- Fellowship Training in Epilepsy, Yale University

James Vornov, MD, PhD
Vice President, Medical Department, Neurology, Analgesia, Psychiatry

Dr. James Vornov is a board-certified neurologist with over 18 years of director level clinical development experience.

Experience Summary
- Brought multiple compounds into first-in-man to proof-of-concept and successful NDA submission. Provided broad clinical trial design expertise, clinical pharmacology experience, operational excellence and global regulatory strategy development across a broad range of CNS diagnostics and therapeutics
- Expertise in the rapid transition of compounds from the laboratory to clinical proof of concept using Critical Path technologies such as biomarkers, PK/PD modeling and clinical trial simulation
- Worked in multiple CNS therapeutic areas having directed programs in Depression, Suicidal Ideation, Parkinson's disease treatment and diagnosis, stroke, neuropathic pain, diabetic and chemotherapy-induced peripheral neuropathies, anesthesia and brain tumors

Education Summary
- Bachelor of Arts, Biology & Psychology, Columbia University
- Doctor of Medicine, Emory University, School of Medicine
- Doctor of Philosophy, Anatomy, Emory University, School of Medicine
Developing effective treatments for psychiatric disorders such as depression, bipolar disorder, anxiety disorders, and schizophrenia requires unique expertise. Medpace medical, regulatory, and operational experts bring a broad range of experience in designing and conducting psychiatric studies for psychiatric clinical development across adult, geriatric, and pediatric populations.

**Indication expertise:**
- Addictive Disorders
- Anxiety Disorders
- Attention-Deficit/Hyperactivity Disorder
- Bipolar Disorder
- Cognition Disorders
- Depression
- Developmental Disorders
- Eating Disorders
- Schizophrenia
- Sleep Disorders
- Neuropsychiatric Disorders

**RECRUITMENT AND SITE RELATIONSHIPS**
With broad neuroscience experience and relationships with Investigators and Key Opinion Leaders (KOLs) worldwide, we can select the best sites for your specific program. We provide in-depth knowledge of screening tools and rating scales and will provide oversight for rater services including subjective assessments, inter-rater reliability, and scale validation.

**SPECIALIZED MEDICAL DEVICE EXPERTISE**
There is a growing number of neurologic and psychiatric devices and diagnostics in various stages of research and development. With a dedicated Medical Device division, Medpace brings together medical and regulatory experts into a collaborative team that understands the nuances from both the drug and device perspectives. Medpace is experienced in helping clients meet regulatory compliance and ensuring patient safety while accelerating their medical device or product to market.
CENTRAL LABS
Medpace Central Labs provide consistency in methods and instrumentation across four wholly-owned and purpose-built laboratories located in the US, Europe, China, and Singapore. We provide safety and efficacy testing to support psychiatric trials. Central labs offer a wide range of relevant biomarker assays and can rapidly establish and validate novel assays as needed. Over the past several years, Medpace has validated hundreds of new biomarker assays based on guidelines from the Clinical and Laboratory Standards Institute (CLSI) and in accordance with CAP and CLIA regulations. With hundreds of thousands of patients screened, Medpace central labs has supported some of the world’s largest and most complex clinical trials.

ClinTrak®, Medpace’s proprietary study management platform, facilitates team coordination and decision support for Sponsors and sites, and ensures global teams can collaborate and maximize efficiency. It supports eDiary/ ePROs, an increasingly important requirement for psychiatric studies while providing real-time global tracking and tracing of specimens.

SPECIALIZED NEURO-IMAGING
High-quality image acquisition and interpretation is crucial for the success of trials relying on neuroimaging for patient selection or as a primary or secondary endpoint. Medpace Imaging Core Lab provides an end to-end suite of imaging services to enhance and expedite biopharmaceutical and imaging contrast agent development, including consultation on imaging biomarker strategies, image acquisition protocols, image collection/archiving services, and image analysis across imaging modalities.

FULL-SERVICE CLINICAL DEVELOPMENT
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective.